Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
Q9cqN1GnHuTG3kEk
Listen
